Federal Register / Vol. 79, No. 241 / Tuesday, December 16, 2014 / Notices 74733 

Cannabinoid Receptor Meditating 

Compounds for Metabolic Disease 

Description of Technology: There is 

evidence that the metabolic effects of 

endocannabinoids are mediated by CB1 

receptors in peripheral tissues. While 

prior attempts at generating CB1 

receptor blockers have had serious 

neuropsychiatric side effects, inventors 

at NIH have discovered compounds that 

block CB1 receptors with reduced brain 

penetrance. In addition, some of these 

compounds also have a direct inhibitory 

effect on inducible nitric oxide synthase 

(iNOS), whereas another group of the 

compounds directly activates AMP 

kinas. These dual-target compounds 

may be useful for treating metabolic 

disease and related conditions such as 

obesity and diabetes and their 

complications, including liver or kidney 

fibrosis, without the dangerous the side 

effects. 

Potential Commercial Applications: 

Treatment of metabolic disease and 

related conditions such as diabetes, 

obesity and fibrotic disease. 

Competitive Advantages: Cannabinoid 

receptor blockers with reduced brain 

penetrance relative to older drugs of this 

class, also having secondary target for 

improved therapeutic efficacy. 

Development Stage: Early-stage. 

Inventors: George Kunos (NIAAA), 

Malliga R. Iyer (NIAAA), Resat Cinar 

(NIAAA), Kenner C. Rice (NIDA). 

Intellectual Property: HHS Reference 

No. E–140–2014/0—U.S. Provisional 

Application No. 61/991,333 filed May 9, 

2014. 

Related Technologies: 

• HHS Reference No. E–211–2006/

0—U.S. Patent No. 8,293,724 issued 

October 23, 2012 

• HHS Reference No. E–282–2012/

0—PCT Application No. PCT/

US2013069686 filed December 11, 2013 

• HHS Reference No. E–103–2013/

0—PCT Application No. PCT/US2014/

043924 filed June 24, 2014 

Licensing Contact: Jaime M. Greene; 

301–435–5559; greenejaime@

mail.nih.gov. 

Octopod (8-Pointed Star-Shape) Iron 

Oxide Nanoparticles Enhance MRI T2

Contrast 

Description of Technology: The 

octopod-shaped iron oxide 

nanoparticles of this technology 

significantly enhance contrast in MRI 

imaging compared to spherical 

superparamagnetic iron oxide 

nanoparticle T2 contrast agents. These 

octopod iron oxide nanoparticles show 

a transverse relaxivity that is over five 

times greater than comparable spherical 

agents. Because the unique octopod 

shape creates a greater effective radius 

than spherical agents, but maintains 

similar magnetization properties, the 

relaxation rate is improved. The 

improved relaxation rate greatly 

enhances the contrast of images. These 

octopod agents appear to be biocompatible and may be suitable for 

intravenous delivery. The synthesis of 

these agents is also easily reproducible 

and scaled. The superior contrast greatly 

improves diagnostic sensitivities, 

compared to current FDA approved 

spherical contrast agents. These 

octopod-shaped iron oxide nanoparticle 

T2 contrast agents may have a number 

of medical imaging uses, such as tumor 

detection, atherosclerosis imaging and 

delivery of therapeutic treatments. 

Potential Commercial Applications: 

Medical imaging, such as tumor 

detection, atherosclerosis imaging and 

delivery of therapeutic treatments. 

Competitive Advantages: 

• Enhanced T2 contrast 

• Reproducible and scalable synthesis 

• Improved imaging and diagnostic 

capability 

Development Stage: In vivo data 

available (animal). 

Inventors: Xiaoyuan Chen (NIBIB), 

Jinhao Gao (Xiamen University, China), 

Zhenghuan Zhao (Xiamen University, 

China). 

Publication: Zhao Z, et al. Octapod 

iron oxide nanoparticles as highperformance T2 contrast agents for 

magnetic resonance imaging. Nat 

Commun. 2013; 4:2266. [PMID 

23903002]. 

Intellectual Property: HHS Reference 

No. E–314–2013/0—PCT Application 

No. PCT/CN2013/076645 filed June 3, 

2013. 

Licensing Contact: Edward (Tedd) 

Fenn; 424–297–0336; tedd.fenn@

nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Biomedical 

Imaging and Bioengineering is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate or 

commercialize this technology. For 

collaboration opportunities, please 

contact Cecilia Pazman, Ph.D. at 

pazmance@mail.nih.gov. 

Dated: December 9, 2014. 

Richard U. Rodriguez, 

Acting Director, Office of Technology 

Transfer, National Institutes of Health. 

[FR Doc. 2014–29319 Filed 12–15–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; Translational. 

Date: January 23, 2015. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hotel Monaco, 700 F Street NW., 

Washington, DC 20004. 

Contact Person: Joel A. Saydoff, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research, 

NINDS/NIH/DHHS/Neuroscience Center, 

6001 Executive Boulevard, Suite 3205, MSC 

9529, Bethesda, MD 20892–9529, 301–496– 

9223, joel.saydoff@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: December 9, 2014. 

Carolyn Baum, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2014–29322 Filed 12–15–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

mstockstill on DSK4VPTVN1PROD with NOTICES

74734 Federal Register / Vol. 79, No. 241 / Tuesday, December 16, 2014 / Notices 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel NIAID Clinical Trial 

Implementation Cooperative Agreement 

(U01) and NIAID Clinical Trail 

Implementation Grant (R01). 

Date: January 9, 2015. 

Time: 1:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 5601 

Fishers Lane, Rockville, MD 20852 

(Telephone Conference Call). 

Contact Person: Jane K. Battles, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, DEA/NIAID/NIH/DHHS, 5601 

Fishers lane Room F30B, Rockville, MD 

20852, 240–669–5029, battlesja@

mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: December 10, 2014. 

David Clary, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2014–29321 Filed 12–15–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Training 

and Career Development Application 

Review. 

Date: March 11, 2015. 

Time: 2:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute Shady 

Grove, 9609 Medical Center Drive, Room 

7W110, Rockville, MD 20850 (Telephone 

Conference Call). 

Contact Person: Robert E. Bird, Ph.D., 

Chief, Resources and Training Review 

Branch, Division of Extramural Activities, 

National Cancer Institute 9609 Medical 

Center Drive, Room 7W110, Bethesda, MD 

20892–9750, 240–276–6344, birdr@

mail.nih.gov. 

Information is also available on the 

Institute’s/Center’s home page: http://

deainfo.nci.nih.gov/advisory/sep/sep.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: December 10, 2014. 

Melanie J. Gray, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2014–29320 Filed 12–15–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Agency Information Collection 

Activities: Generic Clearance for the 

Collection of Qualitative Feedback on 

Agency Service Delivery 

AGENCY: Department of Homeland 

Security. 

ACTION: 30-Day Notice and request for 

comments; Extension without change of 

a currently approved collection, 1601– 

0014. 

SUMMARY: The Department of Homeland 

Security will submit the following 

Information Collection Request (ICR) to 

the Office of Management and Budget 

(OMB) for review and clearance in 

accordance with the Paperwork 

Reduction Act of 1995 (Pub. L. 104–13, 

44 U.S.C. Chapter 35). DHS previously 

published this information collection 

request (ICR) in the Federal Register on 

Tuesday, September 9, 2014 at 79 FR 

53435 for a 60-day public comment 

period. No comments were received by 

DHS. The purpose of this notice is to 

allow additional 30-days for public 

comments 

DATES: Comments are encouraged and 

will be accepted until January 15, 2015. 

This process is conducted in accordance 

with 5 CFR 1320.1. 

ADDRESSES: Interested persons are 

invited to submit written comments on 

the proposed information collection to 

the Office of Information and Regulatory 

Affairs, Office of Management and 

Budget. Comments should be addressed 

to OMB Desk Officer, Department of 

Homeland Security and sent via 

electronic mail to oira_submission@

omb.eop.gov or faxed to (202) 395–5806. 

SUPPLEMENTARY INFORMATION: The 

information collection activity will 

garner qualitative customer and 

stakeholder feedback in an efficient, 

timely manner, in accordance with the 

Administration’s commitment to 

improving service delivery. By 

qualitative feedback we mean 

information that provides useful 

insights on perceptions and opinions, 

but are not statistical surveys that yield 

quantitative results that can be 

generalized to the population of study. 

This feedback will provide insights into 

customer or stakeholder perceptions, 

experiences and expectations, provide 

an early warning of issues with service, 

or focus attention on areas where 

communication, training or changes in 

operations might improve delivery of 

products or services. These collections 

will allow for ongoing, collaborative and 

actionable communications between the 

Agency and its customers and 

stakeholders. It will also allow feedback 

to contribute directly to the 

improvement of program management. 

Feedback collected under this generic 

clearance will provide useful 

information, but it will not yield data 

that can be generalized to the overall 

population. This type of generic 

clearance for qualitative information 

will not be used for quantitative 

information collections that are 

designed to yield reliably actionable 

results, such as monitoring trends over 

time or documenting program 

performance. Such data uses require 

more rigorous designs that address: the 

target population to which 

generalizations will be made, the 

sampling frame, the sample design 

(including stratification and clustering), 

the precision requirements or power 

calculations that justify the proposed 

sample size, the expected response rate, 

methods for assessing potential 

nonresponse bias, the protocols for data 

collection, and any testing procedures 

that were or will be undertaken prior 

fielding the study. Depending on the 

degree of influence the results are likely 

to have, such collections may still be 

mstockstill on DSK4VPTVN1PROD with NOTICES